Daratumumab and Minimal Residual Disease in CEPHEUS for Transplant-Ineligible Newly Diagnosed Mult

Study overview

The PubMed record describes a clinical trial titled “Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS.” The article appears in Blood Advances (2026 Aug 25;10(16):5594-5606) and focuses on evaluation of minimal residual disease (MRD) in patients who were deemed transplant-ineligible or whose transplant was deferred. The therapeutic agent under investigation is daratumumab. The PubMed entry classifies the work as a Clinical Trial and provides bibliographic identifiers for retrieval.

Authors and affiliations

The PubMed entry lists Sonja Zweegman as the first author and names a large, international group of coauthors representing academic centers and clinical sites across Europe, North America, Asia, South America, and industry (including multiple Johnson & Johnson affiliates). The affiliations encompass university hospitals, comprehensive cancer centers, and company research sites. The record documents the multi-institutional nature of the study but the excerpt does not include author-contributed sections such as the full abstract, methods, results, or conclusion text.

Publication and indexing details

• Journal: Blood Advances
• Publication date and citation: 2026 Aug 25;10(16):5594-5606
• DOI: 10.1182/bloodadvances.2026019937
• PMID: 42234958
• PMCID: PMC13495367
• Article type: Clinical Trial

These identifiers enable locating the complete article and supporting materials in bibliographic databases and PubMed Central.

Full-text access and links

The PubMed record includes a link to the free full-text article on PubMed Central (PMCID PMC13495367) and a link to the publisher site via Blood Advances. Users seeking methods, MRD assay details, endpoint definitions, statistical analysis, and full outcome data should consult the full-text article via the DOI or PMCID.

What the PubMed excerpt reports

From the provided PubMed excerpt we can confirm: the study title, that it is a clinical trial of daratumumab in transplant-ineligible or -deferred newly diagnosed myeloma with focus on minimal residual disease in the CEPHEUS study, the full author list and institutional affiliations, journal citation, and indexing metadata (PMID, PMCID, DOI). The entry confirms international collaboration and industry involvement.

Key missing details and data not provided

The supplied PubMed excerpt does not include the study abstract or full text content with outcomes. Specifically, the following critical elements were not reported in the provided source excerpt and therefore cannot be summarized here:

• Trial design particulars (randomization, control arm, open-label vs blinded, phase, sample size).
• Eligibility criteria beyond the high-level phrase “transplant-ineligible or -deferred newly diagnosed.”
• MRD assay methodology (technique used, sensitivity threshold, timing of assessments).
• Primary and secondary endpoints and their prespecified definitions.
• Numerical MRD results (rates of MRD negativity, time to MRD negativity).
• Efficacy outcomes such as overall response rate, progression-free survival, or overall survival.
• Safety and adverse event data.
• Statistical analysis details, confidence intervals, p-values, or subgroup analyses.
• Authors’ interpretation, limitations, and clinical recommendations.

Because these data elements are not included in the excerpt, any statements about efficacy, safety, or clinical impact would be speculative and are therefore omitted.

Practical next steps for clinicians and researchers

• Retrieve and review the full-text article (PMCID PMC13495367 or DOI 10.1182/bloodadvances.2026019937) to evaluate study design, MRD methods and thresholds, numerical results, and authors’ conclusions.
• Examine supplementary materials and figures referenced in the full text for detailed MRD data and subgroup analyses.
• Review conflict-of-interest and funding disclosures in the full article to understand industry involvement.
• If planning to apply findings to practice, assess external validity relative to your patient population (age, comorbidity, transplant eligibility criteria) and confirm whether MRD assessments used in CEPHEUS are available and validated in your setting.

Summary

The PubMed entry documents a multicenter clinical trial investigating daratumumab with a focus on minimal residual disease in transplant-ineligible or -deferred newly diagnosed multiple myeloma (CEPHEUS). The record provides full bibliographic metadata and author/affiliation listings, and it links to a free full text. However, the provided excerpt does not include trial methods, numerical MRD outcomes, efficacy or safety results, or authors’ conclusions. To obtain complete, actionable information, consult the full text via the PMCID or DOI.